The German CDMO Vetter has announced the expansion of its fill-and-finish network with the addition of ten more commercial filling lines.
The firm said the new lines were part of its long-term investment programme.
Seven of the ten planned manufacturing lines are being implemented across Vetter’s existing sites, with the first new line, designed to fill pre-sterilised syringes, recently becoming operational.
The company said that a second line is expected to follow by the end of this year, with another five lines for aseptic production planned through 2028.
The remaining three lines are planned for Vetter’s new commercial site in Saarlouis, Germany, which is expected to become operational by 2031.
“Pharma and biotech companies seek partners with a proven track record, operational expertise and the capabilities to support their current and future drug products,” said Managing Director Henryk Badack, "This demand is reflected in our strategy for sustainable growth."
Through our ongoing investments, we are expanding our global manufacturing resources and strengthening our ability to support customers throughout the lifecycle of their products in international markets.
Vetter said it is also investing in its broader operational infrastructure, including expanding compounding, pharmaceutical storage and visual inspection capabilities, as well as implementing advanced cleanroom technology and increased automation and digitalisation.
“Our phased approach enables us to make additional capacity available while systematically expanding our global production network,” added Managing Director Carsten Press.
These investments provide customers with scalable operations, well-managed supply chains and high-quality aseptic manufacturing to support their long-term growth.
The CDMO will be exhibiting at CPHI Milan from October 6 to 8, 2026, at booth 6A52.
